Pacer Advisors
SUPN icon

Pacer Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Pacer Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Sell
216
-57
-21% -$2.74K ﹤0.01% 2351
2026
Q1 		$14K Buy
273
+101
+59% +$5.14K ﹤0.01% 2142
2025
Q4 		$8.55K Sell
172
-190,722
-100% -$9.27M ﹤0.01% 3646
2025
Q3 		$9.12M Sell
190,894
-97,337
-34% -$3.92M 0.02% 504
2025
Q2 		$9.09M Sell
288,231
-115,397
-29% -$3.7M 0.02% 517
2025
Q1 		$13.2M Sell
403,628
-1,193,828
-75% -$42.3M 0.03% 408
2024
Q4 		$57.8M Sell
1,597,456
-155,426
-9% -$5.47M 0.12% 183
2024
Q3 		$54.7M Buy
1,752,882
+403,028
+30% +$12.6M 0.12% 199
2024
Q2 		$36.1M Buy
1,349,854
+1,348,508
+100,186% +$39.1M 0.08% 241
2024
Q1 		$45.9K Buy
1,346
+716
+114% +$21.3K ﹤0.01% 3201
2023
Q4 		$18.2K Buy
630
+327
+108% +$8.67K ﹤0.01% 3329
2023
Q3 		$8.35K Sell
303
-448,692
-100% -$13.7M ﹤0.01% 2574
2023
Q2 		$13.5M Buy
+448,995
New +$15.7M 0.05% 304
2023
Q1 		– Sell
-277,169
Closed -$9.89M – 2366
2022
Q4 		$9.89M Buy
+277,169
New +$9.63M 0.05% 341
2021
Q4 		– Sell
-90,866
Closed -$2.42M – 2225
2021
Q3 		$2.42M Sell
90,866
-5,168
-5% -$139K 0.03% 633
2021
Q2 		$2.96M Buy
96,034
+40,518
+73% +$1.24M 0.04% 503
2021
Q1 		$1.45M Buy
55,516
+37,016
+200% +$1.04M 0.03% 622
2020
Q4 		$465K Buy
18,500
+3,077
+20% +$66.2K 0.01% 999
2020
Q3 		$321K Buy
15,423
+7,406
+92% +$168K 0.01% 1112
2020
Q2 		$190K Sell
8,017
-2,083
-21% -$46K ﹤0.01% 810
2020
Q1 		$201K Sell
10,100
-10,751
-52% -$226K ﹤0.01% 414
2019
Q4 		$495K Sell
20,851
-2,452
-11% -$59.5K 0.02% 784
2019
Q3 		$640K Buy
23,303
+7,005
+43% +$208K 0.01% 944
2019
Q2 		$539K Buy
16,298
+2,240
+16% +$76.7K 0.01% 955
2019
Q1 		$493K Buy
14,058
+2,098
+18% +$78.1K 0.01% 578
2018
Q4 		$397K Buy
+11,960
New +$514K 0.01% 162

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Pacer Advisors's SUPN Position: Q2 2026 in Review

Pacer Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 21% in Q2 2026, selling an estimated $2.74K and leaving 216 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #2351.

Pacer Advisors first reported a position in SUPN in Q4 2018 and has held it in 26 quarters since. The position peaked at $57.8M in Q4 2024. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Pacer Advisors held 216 shares of Supernus Pharmaceuticals worth $10K as of Q2 2026.
  • Pacer Advisors sold 57 Supernus Pharmaceuticals shares in Q2 2026, an estimated $2.74K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2351 holding.
  • Pacer Advisors first reported a position in Supernus Pharmaceuticals in Q4 2018 and has held it in 26 quarters since.
  • Pacer Advisors's Supernus Pharmaceuticals position peaked at $57.8M in Q4 2024.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.